Bluejay Diagnostics Inc. (BJDX) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for BJDX, including 3 SEC filings, 2 market updates and 1 13D/G filing. The most recent was published Nov 13, 2026.
Financial highlights
Full financials- Net income, TTM
- -$7.68M
- Cash
- $7.38M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks46+50%
2026-05-172026-11-08
Mix1790d
- SEC Filings6(35%)
- Insider5(29%)
- Market4(24%)
- Other1(6%)
- 13D/G1(6%)
Activity · 52 weeks7443 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECSEC Form 10-Q filed by Bluejay Diagnostics Inc.10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- NEWSBluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business UpdateCompletes SYMON-II clinical study enrollment and advances clinical validation activities.Achieves critical manufacturing milestone ahead of contractual deadline, strengthening supply chain and commercialization readiness.Targets FDA 510(k) submission in the first half of 2027. ACTON, MA / ACCESS Newswire / November 12, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid, near-patient testing solutions for critical care, today reported financial results for the quarter ended September 30, 2026, and provided an update on its clinical, regulatory and manufacturing progress for the Symphony™ platform. During the quar
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Bluejay Diagnostics Inc.SCHEDULE 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- NEWSBluejay Diagnostics Announces 1-for-4 Reverse Stock SplitACTON, MA / ACCESS Newswire / October 30, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 3, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 3, 2026 under the Company's existing trading symbol, "BJDX." At such time, th
- SECSEC Form 8-K filed by Bluejay Diagnostics Inc.8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- NEWSBluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization ReadinessCompany Achieves Toray Contractual Milestone with Establishment of Manufacturing Site ACTON, MA / ACCESS Newswire / October 13, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that it has completed the establishment of a manufacturing site for Symphony™ cartridges, achieving a critical contractual milestone as the Company advances toward regulatory submission and potential commercialization. The milestone was achieved ahead of the October 23, 2026 contractual deadline established under Bluejay's amended license agreem
- SECSEC Form 8-K filed by Bluejay Diagnostics Inc.8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- NEWSBluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic ShockSYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission ACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced baseline clinical characteristics from the SYMON-II clinical validation study, highlighting a substantial and diverse population of critically ill patients and clinically meaningful mortality events for evaluating interleukin-6 ("IL-6") as a biomarker associated with 28-day mortality risk in patien
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare MarketsACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, and Lovell Government Services, Inc. ("Lovell"), a Service-Disabled Veteran-Owned Company ("SDVOSB") specializing in federal healthcare distribution, today announced a distribution, co-marketing and strategic partnership designed to support the introduction of Bluejay’s products into the U.S. federal healthcare market following applicable U.S. Food and Drug Administration ("FDA") clearance or other required regulatory authorization
- INSIDERPresident and CEO Dey Indranil was granted 28,000 shares, increasing direct ownership by 224% to 40,522 units (SEC Form 4)4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- INSIDERSEC Form 4 filed by Director Dey Svetlana4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- INSIDERSEC Form 4 filed by Director Wurth Douglas Clark4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- INSIDERSEC Form 4 filed by Director Zeidman Fred S4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- INSIDERSEC Form 4 filed by Director Chase Donald R4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Bluejay Diagnostics Inc.SCHEDULE 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
- SECSEC Form SCHEDULE 13G filed by Bluejay Diagnostics Inc.SCHEDULE 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and CommercializationSYMON-II pivotal clinical study completes targeted enrollment of 750 patientsCompany advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain riskCompany ends second quarter with approximately $9.6 million in cash following significant financing ACTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes in critical care settings, today reported financial results for the quarter ended June 30, 2026 and provided an update on the Company’s clinical, regulatory and manufacturing progress. During th
- SECSEC Form S-8 filed by Bluejay Diagnostics Inc.S-8 - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECSEC Form 10-Q filed by Bluejay Diagnostics Inc.10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- INSIDERSEC Form 4 filed by Large owner Bank Of America Corp /De/4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
BJDX FAQ
10 questionsWhat does Bluejay Diagnostics Inc. do?
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19...What is the latest news on BJDX?
In the last 30 days Quantisnow tracked 6 wire items for BJDX: 3 SEC filings, 2 market updates and 1 13D/G filing. The most recent was published on November 13, 2026.Is BJDX profitable?
No. Bluejay Diagnostics Inc. reported a net loss of $7.68M for the twelve months ended Sep 30, 2026.How much cash and debt does BJDX have?
Bluejay Diagnostics Inc. reported $7.38M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does BJDX stock trade?
Bluejay Diagnostics Inc. (BJDX) is listed on NASDAQ.What sector and industry is BJDX in?
Bluejay Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Bluejay Diagnostics Inc. go public?
Bluejay Diagnostics Inc. (BJDX) completed its IPO in 2021.What are analysts saying about BJDX?
Bluejay Diagnostics Inc. has had 1 recent analyst action on file. The most recent action was from Dawson James: Buy with a $10.00 price target on 2022-01-12. Recent price targets cluster around $10.00.What companies are similar to BJDX?
Notable peers in the same industry include ABT (Abbott Laboratories), QDEL (QuidelOrtho Corporation), DHR (Danaher Corporation), BIO (Bio-Rad Laboratories Inc.). Compare BJDX side-by-side with any of them on Quantisnow.How can I track BJDX on Quantisnow?
Quantisnow aggregates Bluejay Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BJDX to receive live email and push alerts on every new disclosure.